Login to Your Account



Pharming Group Earns $6.9M Milestone for Ruconest Work

By Nuala Moran


Wednesday, November 3, 2010

LONDON – After more than a decade in clinical development, Pharming Group NV completed the final stage of European approval for its lead product Ruconest, in the treatment of acute attacks of hereditary angioedema (HAE), triggering the payment of a €5 million (US$6.94 million) milestone payment from marketing and distribution partner Swedish Orphan Biomedical AB. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription